Is BMY.SW stock a buy after the intraday drop?

BMY.SW stock shows a short-term buying opportunity if price confirms reversal above **CHF43.20**. Use a tight stop under **CHF42.00** and target **CHF44.50**. This is a tactical oversold bounce, not a long-term recommendation.

What is Meyka AI's forecast for BMY.SW stock?

Meyka AI's forecast model projects **CHF39.34** for BMY.SW stock over 12 months, implying **-7.51%** from current price **CHF42.54**. Forecasts are model-based projections and not guarantees.

Which levels matter for intraday trading of BMY.SW stock?

Watch support at the day low **CHF42.54**, short-term resistance **CHF43.30–43.50**, and prior close **CHF44.50**. A breakout above **CHF44.50** suggests wider recovery; failure below **CHF42.00** increases downside risk.

How does BMY.SW stock compare to the Healthcare sector?

BMY.SW stock trades at **PE 15.81**, well below the Healthcare sector average **PE 33.70**, indicating relative valuation appeal. High leverage and payout ratio remain sector-relative risks to monitor.

CH Stocks

BMY.SW Bristol-Myers Squibb (SIX) CHF42.54 16 Feb 2026: intraday bounce possible

ByHuzaifa Zahoor February 16, 2026February 16, 2026

BMY.SW stock opened the intraday session at CHF42.54 after a -4.40% drop from yesterday’s close, setting a clear oversold bounce setup on the SIX (Switzerland) tape. Volume is light at 500 shares but relative volume is elevated at 22.73x, which signals concentrated trading interest. Traders should treat moves as short-term reaction, watch risk controls, and compare bounce targets against the year high CHF44.75 and previous close CHF44.50.